Table 2. Logistic regression of predictive variable of csPCa in the model including the PV assessed with MRI and the model including the PVC assessed with DRE.
| Predictive variable | Model with MRI-PV | Model with DRE-PVC | ||
|---|---|---|---|---|
| Odds ratio (95% CI) | p-value | Odds ratio (95% CI) | p-value | |
| Age (ref. previous year) | 1.06 (1.04–1.08) | <0.001 | 1.05 (1.04–1.07) | <0.001 |
| Serum PSA (ref. previous ng/mL) | 1.03 (1.02–1.07) | 0.032 | 1.01 (1.00–1.01) | 0.027 |
| DRE (ref. normal) | 1.62 (1.24–2.11) | <0.001 | 1.68 (1.29–2.18) | <0.001 |
| MRI-PV (ref. previous mL) | 0.98 (0.81–0.98) | <0.001 | - | - |
| DRE-PVC (ref. small) | - | - | 0.56 (0.47–0.66) | <0.001 |
| Type of biopsy (ref. initial) | 0.71 (0.55–0.92) | 0.009 | 1.63 (0.49–0.81) | <0.001 |
| PCa family history (ref, no.) | 1.07 (1.01–1.18) | 0.029 | 1.79 (1.05–1.12) | 0.036 |
| PI-RADS score (ref. 1) | 3.16 (2.69–3.71) | <0.001 | 3.24 (2.77–3.79) | <0.001 |
csPCa: clinically significant PCa, MRI: magnetic resonance imaging, DRE: digital rectal examination, CI: confidence interval, Ref: reference, PSA: prostate-specific antigen, PVC: prostate volume category, PCa: prostate cancer, PI-RADS: prostate imaging-report and data system.